Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Lexicon Pharmaceuticals, Inc.    LXRX

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 77,3 M
EBIT 2016 -151 M
Net income 2016 -152 M
Debt 2016 -
Yield 2016 -
Sales 2017 114 M
EBIT 2017 -163 M
Net income 2017 -161 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 21,9x
Capi. / Sales2017 14,9x
Capitalization 1 695 M
More Financials
Company
Lexicon Pharmaceuticals, Inc. engages in discovery and development of breakthrough treatments for human disease.The company primarily focuses on the discovery of the functions and pharmaceutical utility of genes and the use of those gene function discoveries in the discovery and development of... 
More about the company
Surperformance© ratings of Lexicon Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on LEXICON PHARMACEUTICALS, I
07/28 LEXICON PHARMACEUTICALS : Announces The Validation By The European Medicine Agen..
07/14 LEXICON PHARMACEUTICALS : To Present At The Cantor Fitzgerald Healthcare Confere..
06/17 LEXICON PHARMACEUTICALS : Assigned Patent
06/16 LEXICON PHARMACEUTICALS : To Present At The Jefferies 2016 Healthcare Conference
06/09 LEXICON PHARMACEUTICALS : Announces The Launch Of Aboutcarcinoid.com To Provide ..
06/09 LEXICON PHARMACEUTICALS : Announces FDA Priority Review Of New Drug Application ..
05/12 LEXICON PHARMACEUTICALS : To Report First Quarter 2016 Financial Results On May ..
05/12 LEXICON PHARMACEUTICALS : To Present At The Bank Of America Merrill Lynch 2016 H..
05/03 LEXICON PHARMACEUTICALS : reports 1Q loss
04/14 LEXICON PHARMACEUTICALS : To Present At The 15th Annual Needham Healthcare Confe..
More news
Sector news : Bio Therapeutic Drugs
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
07/29DJSanofi Profit Down as Diabetes Drug Sales Slip
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2015 SEEKING ALPHA'S BIOTECH WEEKLY : A Gilead Victory, Celladon Crumbles, And More
2015 Lexicon Undervalued As It Approaches A Major Event
2015 Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q1 2015 Results - Earning..
2015 Lexicon Pharmaceuticals EPS in-line, beats on revenue
2015 Lexicon Pharmaceuticals - A Diamond In The Rough?
Advertisement
Chart LEXICON PHARMACEUTICALS, I
Duration : Period :
Lexicon Pharmaceuticals, I Technical Analysis Chart | LXRX | US5288721047 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 20,5 $
Spread / Average Target 26%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lonnel Coats President, Chief Executive Officer & Director
Raymond Debbane Chairman
John Northcott VP-Marketing, Commercial Strategy & Operations
Jeffrey L. Wade CFO, EVP-Corporate & Administrative Affairs
Pablo Lapuerta Chief Medical Officer & EVP-Clinical Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
LEXICON PHARMACEUTICAL..12.10%1 695
AMGEN, INC.5.98%129 232
GILEAD SCIENCES, INC.-21.46%105 840
CELGENE CORPORATION-6.32%86 960
REGENERON PHARMACEUTIC..-21.69%44 671
VERTEX PHARMACEUTICALS..-22.91%23 993
More Results